Clinical impact of antipsychotic and benzodiazepine reduction: findings from a multicomponent psychotropic reduction program within long-term aged care.
Daniel Jake HoyleGregory M PetersonIvan K BindoffLisa M ClinnickAidan D BindoffJuanita L BreenPublished in: International psychogeriatrics (2020)
Antipsychotic and benzodiazepine dose reduction in LTCFs was not associated with deterioration in neuropsychiatric symptoms, QoL, or social withdrawal. Trends toward improved agitation with antipsychotic and benzodiazepine dose reduction require further evaluation in larger, prospective, controlled studies.